The US Food and Drug Administration has approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ‘For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life-expectancy is typically low,’ commented Richard Pazdur, MD, Director of [...]
A study has found that antiplatelet drugs, such as aspirin, are often inappropriately prescribed in acutely hospitalised older people. Antiplatelet drugs are typically used to prevent conditions such as heart attacks and strokes, both for individuals at high risk (primary prevention) and for those who have already experienced one of these events (secondary prevention). In [...]
New research, conducted by a research team from the University of Liverpool and Alder Hey Children’s Hospital, aims to help solve the problem of dose optimisation of children’s medicines. Historically, there has been very little focus on paediatric clinical pharmacology, and there are still a lot of unknowns with regard to optimally delivering medicines to [...]
Closthioamide, discovered in 2010, might eventually offer an alternative for current drugs that are becoming less effective against gonorrhoea. The World Health Organisation (WHO) has estimated that 700,000 people around the world die annually from drug-resistant infections. It also listed drug-resistant gonorrhoea, a sexually transmitted disease caused by the Neisseria gonorrhoeae bacterium, as a high [...]
A scheme launched by the Department of Health in 2011 to help patients stick to their drug regimens has been so successful, that in its first five years, it will save NHS England £517.6 million in the long-term, a team of health economists has found. Lead researcher, Professor Rachel Elliott, from the University of Manchester, [...]
The US Food and Drug Administration has approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate-to-severe kidney disease and those who are on dialysis. Mavyret is also approved for adult patients with HCV genotype 1 infection [...]
